In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes

Journal of Biomaterials Applications

Volumn 29, Issue 4, 2014, Pages 524-542

  Erdemli, Özge ^a   Özen, Seza ^b   Keskin, Dilek ^a   Usanmaz, Ali ^a   Batu, Ezgi Deniz ^b   Atilla, Bülent ^b   Tezcaner, Ayşen ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

amphiphilic triblock copolymer; anti tumor necrosis factor drugs; Etanercept; intra articular delivery; methoxy poly(ethylene glycol) poly( caprolactone) methoxy poly(ethylene glycol); microspheres; rheumatoid arthritis

Indexed keywords

ALIPHATIC COMPOUNDS; BIOMEDICAL MATERIALS; CELL CULTURE; CELL DEATH; DISEASES; DRUG INTERACTIONS; ETHYLENE; ETHYLENE GLYCOL; GLYCOPROTEINS; HYDROPHILICITY; MACROPHAGES; MICROSPHERES; POLYETHYLENE GLYCOLS; POLYOLS; PROTEINS; TARGETED DRUG DELIVERY; TUMORS;

AMPHIPHILIC TRIBLOCK COPOLYMERS; ANTI-TUMORS; ETANERCEPT; INTRA-ARTICULAR DELIVERY; METHOXYPOLYETHYLENE GLYCOL; RHEUMATOID ARTHRITIS;

CONTROLLED DRUG DELIVERY;

COLLAGENASE 3; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL) POLY(EPSILON CAPROLACTONE) METHOXYPOLY(ETHYLENE GLYCOL); MICROSPHERE; PHOSPHATE BUFFERED SALINE; POLYCAPROLACTONE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; BIOMATERIAL; CYTOKINE; DELAYED RELEASE FORMULATION; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE; METHOXY POLY(ETHYLENE GLYCOL)-POLY(EPSILON-CAPROLACTONE)-METHOXY POLY(ETHYLENE GLYCOL); POLYESTER; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; MALE; MICROENCAPSULATION; PARTICLE SIZE; RHEUMATOID ARTHRITIS; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; SYNOVIAL FLUID; SYNOVIOCYTE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; EVALUATION STUDY; INTRAARTICULAR DRUG ADMINISTRATION; MATERIALS TESTING; METABOLISM; PATHOLOGY; SYNOVIUM;

ARTHRITIS, RHEUMATOID; BIOCOMPATIBLE MATERIALS; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN G; IN VITRO TECHNIQUES; INFLAMMATION MEDIATORS; INJECTIONS, INTRA-ARTICULAR; MATERIALS TESTING; MATRIX METALLOPROTEINASES; MICROSPHERES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907146261     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328214535958     Document Type: Article

References (58)

1. Lipsky PE Harrison's rheumatology. 2 nd ed. New York: McGraw-Hill, 2010, pp. 82-99. Fauci A Langford CM, ed. New York: McGraw-Hill ; 2010: 82-99.
2. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008 ; 223: 252-270
3. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol. 2009 ; 27: 1-27
4. Feldmann M. Pathogenesis of arthritis: Recent research progress. Nat Immunol. 2001 ; 2: 771-773
5. MacNaul KL, Chartrain N, Lark M, et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem. 1990 ; 265: 17238-17245
6. Agarwal S, Misra R, Aggarwal A. Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. Rheumatol Int. 2009 ; 29: 907-911
7. Frank S, Peters MA, Wehmeyer C, et al. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by SUMO-2/3 through the transcription factor NF-kappaB. Ann Rheum Dis. 2013 ; 72: 1874-1881
8. Gattorno M, Gerloni V, Morando A, et al. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol. 2002 ; 29: 1774-1779
9. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol. 2010 ; 32: 43-53
10. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther. 2005 ; 7: 29-37
11. Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB, et al. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders. BioDrugs. 2013 ; 27: 439-452
12. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006 ; 54: 1122-1131
13. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999 ; 103: 1345-1352
14. Rodeghero R, Cao Y, Olalekan SA, et al. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. J Immunol. 2013 ; 190: 5423-5435
15. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996 ; 183: 2593-2603
16. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998 ; 160: 3513-3521
17. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007 ; 370: 1861-1874
18. Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007 ; 179: 1872-1883
19. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003 ; 48: 2122-2127
20. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004 ; 22: S134-140
21. Adriaansen J, Khoury M, de Cortie CJ, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis. 2007 ; 66: 1143-1150
22. Bliddal H, Terslev L, Qvistgaard E, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol. 2006 ; 35: 341-345
23. Bliddal H, Terslev L, Qvistgaard E, et al. Safety of intra-articular injection of etanercept in small-joint arthritis: An uncontrolled, pilot-study with independent imaging assessment. Joint Bone Spine. 2006 ; 73: 714-717
24. Boesen M, Boesen L, Jensen KE, et al. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: Magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol. 2008 ; 35: 584-591
25. Kim KK, Pack DW BioMEMS and biomedical nanotechnology. Ferrari M Lee AP Lee LJ, ed. New York: Springer ; 2006: 19-50.
26. Woodruff MA, Dietmar W. The return of a forgotten polymer: Polycaprolactone in the 21st century. Prog Polym Sci. 2010 ; 35: 1217-1256
27. Sinha VR, Bansal K, Kaushik R, et al. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharm. 2004 ; 278: 1-23
28. Dash TK, Konkimalla VB. Polymeric modification and its implication in drug delivery: Poly-epsilon-caprolactone (PCL) as a model polymer. Mol Pharm. 2012 ; 9: 2365-2379
29. Wei X, Gong C, Gou M, et al. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm. 2009 ; 381: 1-18
30. Lemmouchi Y, Perry MC, Amass AJ, et al. Novel synthesis of biodegradable amphiphilic linear and star block copolymers based on poly(epsilon-caprolactone) and poly(ethylene glycol). J Polym Sci Pol Chem. 2007 ; 45: 3975-3985
31. Zhou S, Deng X, Yang H. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) block copolymers: Characterization and their use as drug carriers for a controlled delivery system. Biomaterials. 2003 ; 24: 3563-3570
32. Jia W, Gu Y, Gou M, et al. Preparation of biodegradable polycaprolactone/poly (ethylene glycol)/polycaprolactone (PCEC) nanoparticles. Drug Deliv. 2008 ; 15: 409-416
33. Gou M, Dai M, Li X, et al. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf B Biointerfaces. 2008 ; 64: 135-139
34. Gou M, Dai M, Gu Y, et al. Basic fibroblast growth factor loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol. 2008 ; 8: 2357-2361
35. Erdemli O Engineering Sciences. Ankara: Middle East Technical University ; 2013 :
36. Erdemli O, Usanmaz A, Keskin D, et al. Characteristics and release profiles of MPEG-PCL-MPEG microspheres containing immunoglobulin G. Colloids Surf B Biointerfaces. 2014 ; 117: 487-496
37. Wong HM, Wang JJ, Wang CH. In vitro sustained release of human immunoglobulin G from biodegradable microspheres. Ind Eng Chem Res. 2001 ; 40: 933-948
38. Cho KY, Lee KS, Park JK. Effect of graft copolymer composition on the compatibility of biodegradable PCL/PCL-g-PEG blend. Polym-Korea. 2009 ; 33: 248-253
39. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008 ; 364: 328-343
40. Fickert S, Fiedler J, Brenner RE. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthrit Cartil. 2003 ; 11: 790-800
41. Butoescu N, Jordan O, Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: A review of the factors influencing their performance. Eur J Pharm Biopharm. 2009 ; 73: 205-218
42. Kaur A, Harikumar SL. Controlled drug delivery approaches for rheumatoid arthritis. J Appl Pharm Sci. 2012 ; 2: 21-32
43. Larsen C, Ostergaard J, Larsen SW, et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008 ; 97: 4622-4654
44. Mumper RJ, Jay M. Poly(L-lactic acid) microspheres containing neutron-activatable holmium-165: A study of the physical characteristics of microspheres before and after irradiation in a nuclear reactor. Pharm Res. 1992 ; 9: 149-154
45. James S Injectable dispersed systems: Formulation, processing, and performance. Florida, USA: Taylor & Francis Group, LLC ; 2005 :
46. Vonarbourg A, Passirani C, Saulnier P, et al. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006 ; 27: 4356-4373
47. Paillard-Giteau A, Tran VT, Thomas O, et al. Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique. Eur J Pharm Biopharm. 2010 ; 75: 128-136
48. Muller M, Voros J, Csucs G, et al. Surface modification of PLGA microspheres. J Biomed Mater Res Part A. 2003 ; 66A: 55-61
49. Oates KM, Krause WE, Jones RL, et al. Rheopexy of synovial fluid and protein aggregation. J R Soc Interface. 2006 ; 3: 167-174
50. Lipowitz AJ Textbook of small animal orthopaedics. Newton CD Nunamaker DM, ed. New York: International Veterinary Information Service ; 1985: 1015-1028.
51. Rinaudo M, Rozand Y, Mathieu P, et al. Role of different pre-treatments on composition and rheology of synovial fluids. Polymers. 2009 ; 1: 16-34
52. Aly MN. Intra-articular drug delivery: A fast growing approach. Recent Pat Drug Deliv Formul. 2008 ; 2: 231-237
53. Kim JH, Bae YH. Albumin loaded microsphere of amphiphilic poly(ethylene glycol)/ poly(alpha-ester) multiblock copolymer. Eur J Pharm Sci. 2004 ; 23: 245-251
54. Li R, Li X, Xie L, et al. Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm. 2009 ; 379: 158-166
55. Pean JM, Boury F, Venier-Julienne MC, et al. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres?. Pharm Res. 1999 ; 16: 1294-1299
56. Verma AK, Chanchal A, Maitra A. Co-polymeric hydrophilic nanospheres for drug delivery: release kinetics, and cellular uptake. Indian J Exp Biol. 2010 ; 48: 1043-1052
57. Kaymakcalan Z, Kalghatgi L, Xiong L. F.76 Differential TNF-neutralizing potencies of adalimumab, etanercept and infliximab. Clin Immunol. 2006 ; 119: S77 - S78
58. Mohammed FF, Smookler DS, Khokha Ann R. Metalloproteinases, inflammation, and rheumatoid arthritis. Rheum Dis. 2003 ; 62 (Suppl II). ii43-ii47